Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet-Reference-Cited by-同舟云学术

Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet

Published:2021-11 Issue: Volume: Page:
ISSN:0211-6995
Container-title:Nefrología
language:en
Short-container-title:Nefrología

Author:

Pereira Luciano Artur Lopes,Meng Catarina,Amoedo Manuel Augusto Gonçalves,Mendes Maria Teresa de Sousa Costa Pinto Ferreira,Marques Marco Alexandre Mateus Prazeres,Frazão João Miguel Machado Dória,Weigert André Luiz Loureiro

Publisher

Elsevier BV

Subject

Nephrology

Reference21 articles.

1. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients;Kalantar-Zadeh;Kidney Int,2006

2. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study;Tentori;Clin J Am Soc Nephrol,2015

3. Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes;Pereira;Clin Kidney J,2018

4. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial;Block;JAMA,2017

5. Wnt/beta-catenin signalling: from plasma membrane to nucleus;Kim;Biochem J,2013

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Biomarkers of Bone Metabolism;Nutrients;2024-02-22

2. Cinacalcet in secondary hyperparathyroidism: evaluation of nutritional status, lipid and inflammatory in chronic kidney disease.;Nutrición Hospitalaria;2024